1998 to 2014 Saw Drop in CVD Hospitalization Rates in Diabetes

Share this content:
1998 to 2014 Saw Drop in CVD Hospitalization Rates in Diabetes
1998 to 2014 Saw Drop in CVD Hospitalization Rates in Diabetes

TUESDAY, Nov. 28, 2017 (HealthDay News) -- Cardiovascular disease (CVD) hospitalization rates have declined in recent years among individuals with and those without diabetes, according to a study published online Nov. 17 in Diabetes Care.

Nilka Ríos Burrows, M.P.H., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues estimated the number of discharges having acute coronary syndrome (ACS), cardiac dysrhythmia, heart failure, hemorrhagic stroke, or ischemic stroke as first-listed diagnosis and diabetes using 1998 to 2014 National Inpatient Sample data. The hospitalization rates were calculated for adults aged ≥35 years using estimates from the population with and the population without diabetes. Trends were analyzed and the average annual percentage change (AAPC) was calculated.

The researchers observed significant declines in the age-adjusted hospitalization rates for ACS (AAPC, −4.6 percent per year), cardiac dysrhythmia (−0.7 percent), heart failure (−3.6 percent), hemorrhagic stroke (−1.1 percent), and ischemic stroke (−2.9 percent) from 1998 to 2014 in the population with diabetes. Significant declines in the rates for these conditions were also seen in the population without diabetes, with the exception of dysrhythmia. Rates in the population with diabetes remained two to four times higher than for the population without diabetes by 2014, with the largest difference seen for heart failure rates.

"CVD hospitalization rates declined significantly in both the population with diabetes and the population without diabetes," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »